EHA Unplugged

European Hematology Association

In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.

Subscribe Listen in podnodRSS feed Show website

186 episodes
Updated Friday

Episodes186

Newest first

Friday · 22 min
Hematology Portraits: Prof Frank Leebeek
In this episode Prof. Frank Leebeek reflects on his career in hematology, highlighting a lifelong commitment to bridging clinical practice and research. From his early interest in fibrinolysis during medical school to his current role as Chair of the Department of Hematology at Erasmus Medical Center and Board member at EHA, Prof. Leebeek shares how a dual commitment to research and patient care has shaped his path. The conversation explores key milestones in bleeding disorders research, including large-scale studies on von Willebrand disease that helped improve awareness, diagnosis, and patient-reported outcomes. Prof. Leebeek also discusses his involvement in pioneering gene therapy trials for hemophilia, which have transformed treatment paradigms and patients’ quality of life, while noting ongoing challenges in access and affordability. Beyond research, he reflects on the importance of collaboration, the value of long-term patient relationships, and the role of European-level initiatives in advancing hematology care. Tune in to hear insights from a leading figure in benign hematology and learn how sustained collaboration and innovation continue to drive progress in the field. Guest: Prof Frank Leebeek Affiliation: Erasmus Medical Center, Rotterdam, The Netherlands    Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA  Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠
July 16 · 18 min
How to Start a Clinical Trial?
What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged, Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal investigator, and how the EHA Clinical Research Training in Hematology (CRTH) program helped shape his path. Prof. Mai reflects on the practical and often underappreciated challenges of clinical trial design—from budgeting and statistical planning to ethical considerations and regulatory requirements. He highlights the importance of mentorship and peer networks, as well as the need for persistence when ideas are ahead of their time. The conversation also explores the skills hematologists need to get started in clinical research, with a clear message: developing trials is a multifaceted process that requires both scientific expertise and hands-on learning. Whether you are early in your career or considering a move into clinical research, this episode offers valuable insights into how to take the first steps, overcome challenges, and ultimately contribute to improving patient care through clinical trials. Guests:  Prof Elias K. Mai Heidelberg University Hospital, Heidelberg, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠
July 3 · 35 min
How Experts Treat Multiple Myeloma
In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma. The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibody-drug conjugates—have reshaped the treatment landscape and informed the latest recommendations. The experts discuss the integration of novel prognostic tools such as minimal residual disease (MRD), circulating tumour cells and mass spectrometry, and their evolving role in risk stratification. The episode also reviews key recommendations for frontline management and provides practical guidance for selecting therapies in relapsed and refractory multiple myeloma. Throughout the discussion, the speakers highlight how the updated guidelines support clinicians in navigating an increasingly complex therapeutic landscape. Guests:  Prof. Meletios Dimopoulos and Prof. Evangelos Terpos National and Kapodistrian University of Athens, Greece Host: Prof. Pieter Sonneveld Erasmus University Medical Center, Rotterdam, The Netherlands Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠
June 22 · 22 min
Where Are We Now With Immunotherapy in Multiple Myeloma?
Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities. Guests:  Dr Paula Rodríguez-Otero Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain  Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠
June 1 · 19 min
Menin Inhibitors to Treat Acute Myeloid Leukemia (AML)
Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation. In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition, identify which AML patient populations are most likely to benefit, and review the current clinical evidence supporting their use in defined molecular subtypes. Guests:  Dr Scott Armstrong Dana-Farber Cancer Institute Prof Marc Raaijmakers Erasmus Medical Center Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠
May 13 · 11 min
How Experts Treat HIV-associated Lymphomas
Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas. In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments. This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL, Burkitt lymphoma, plasmatic lymphoma, and more. Finally, Prof Hubel advocates for the inclusion of people living with HIV in lymphoma clinical trials to increase evidence base on HIV-associated lymphomas and improve the care for this specific patient populations. Link to the guideline: Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - Hübel - 2024 - HemaSphere - Wiley Online Library Guest:  Prof Kai Hübel Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠
May 7 · 18 min
Hematology Portraits: Associate Prof Meritxell Alberich Jordà
Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia. Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding about leading a lab. Tune in to hear what she wishes she’d known at the very beginning of her journey. Guest: Associate Prof Meritxell Alberich Jordà Institute of Molecular Genetics of the Czech Academy of Sciences, Laboratory of Haematooncology Head, Prague, Czech Republic The Childhood Leukaemia Investigation Prague in the Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠Provide Feedback⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠ Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠ LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠
April 23 · 18 min
How Experts Treat Large B-cell Lymphoma (LBCL)
Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (⁠Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library).⁠ Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines,  walk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up. Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our guests explain treatment strategies for first-line and relapse/refractory patient populations, highlighting the practice-changing introduction of CAR T therapy in second-line for eligible patients. Finally, they discuss the disparities of access to innovative treatments across Europe and explore future perspectives of LBCL management in Europe and beyond. Guests: Prof Catherine Thieblemont and Prof Marie José Kersten. Professor Catherine Thieblemont from Saint-Louis Hospital in Paris. Professor Marie José Kersten from Amsterdam University Medical Centers (UMC) Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠
April 10 · 25 min
Connecting Hematology Research and Real Life: Peter Kapitein
In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies. Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠ Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠
April 3 · 29 min
How Experts Treat Peripheral T- and NK-cell Lymphomas
Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy). In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell lymphomas. Our guests explain the conscious effort of the guidelines panel to provide evidence based detailed recommendations for each subtype of PTCLs to improve diagnosis, treatment, and follow up. The emphasis is on moving away from “one size fits all” DLBCL style approach toward entity- adapted strategies. Throughout the conversation, they stress the need to read the full guideline – including the supplementary material – and the importance of a multidisciplinary approach by experienced hematopathologists, ideally in expert or reference centres to give patients the best chance of appropriate, modern therapy. GuestS: Prof Francesco D'Amore and Prof Massimo Federico. Professor Francesco D'Amore is a Clinical Professor and Chair of the Department of Hematology at Aarhus University in Denmark Professor Massimo Federico is a Senior Professor of Medical Oncology at the University of Modena and Reggio Emilia in Italy Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠Provide Feedback⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠ Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠ LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠
March 16 · 17 min
Hematology Portraits: Prof Konstanze Döhner
Join EHA President  Prof  Konstanze Döhner  from  University Hospital Ulm in Germany as she discusses her deep interest in hematology, both in research and in the clinics.  Listen as  Prof. Döhner shares why she decided to focus on Acute Myeloid Leukemia (AML) and myeloproliferative neoplasms (MPNs) in her career as a medical doctor, a researcher and a educator.  Tune in to hear  Prof. Döhner describe her journey to becoming the EHA president and her reflections on the current challenges in the hematology field and the solutions she proposes to address those. Guest: Prof Konstanze Döhner, University Hospital Ulm, Germany  Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠Provide Feedback⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠https://ehaedu.org/Campus⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠ Facebook: ⁠⁠https://e-h-a.link/facebook⁠⁠ LinkedIn: ⁠⁠https://www.linkedin.com/company/eha/⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠https://eha.news/subscribe⁠⁠
February 27 · 26 min
How Blood Cells Age: From Stem Cells to Clones (with Dr Michael Milsom)
In this episode, Dr Michael Milsom discusses how thehematopoietic system aging is a complex process with multiple causes. Dr Milsom proposes a more holistic view of the driving mechanisms of hematopoietic andimmune aging that does not focus solely on HSCs. He describes how inflammation‑driven stem cell activation and proliferation cause functional attrition and clonalselection of HSCs, contributing to clonal hematopoiesis. Learn about the mechanisms of blood cells aging andpotential interventions to slow down the process. Guest: Dr Michael Milsom Head of the Division of Experimental Hematology at the German Cancer Research Center, (DKFZ), and group leader at the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI‑STEM), Heidelberg, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠Provide Feedback⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠https://ehaedu.org/Campus⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠ Facebook: ⁠https://e-h-a.link/facebook⁠ LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠
February 6 · 15 min
How Experts Treat Mantle Cell Lymphoma (with Prof Mats Jerkeman)
Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) with Prof Mats Jerkeman (Lund University, Sweden). In this episode, he explains how biological risk factors, particularly TP53 mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including the expanding role of BTK inhibitors (such as ibrutinib) in first-line regimens. He further discusses the management relapsed/refractory MCL, where BTK inhibitors and CAR T-cell therapy have largely supplanted but not fully replaced allogeneic transplantation. Throughout the conversation, Prof Jerkeman emphasizes the dynamic evolution of MCL treatment and the need for ongoing guideline updates as new evidence emerges. Link to the guideline: (EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library) Link to Lund University: Mats Jerkeman - Lund University Home | Lund University Learn More Interested in more content related to CART? We've got you covered. Check out free CART program on ⁠EHA Campus⁠. What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠Provide Feedback⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠https://ehaedu.org/Campus⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠ Facebook: ⁠https://e-h-a.link/facebook⁠ LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠
January 30 · 12 min
Life After CAR T-cell Therapy: Jonathan Clark’s Journey with Mantle Cell Lymphoma and the Future of Patient Advocacy
[This is a Rerelease. Episode first published on July 19, 2024.]Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma. Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission. Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions. Host: Dr Sarah de Vlieger Guest: Jonathan Clark This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024. Learn More Interested in more content related to CART? We've got you covered. Check out free CART program on ⁠EHA Campus⁠. What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠Provide Feedback⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠https://ehaedu.org/Campus⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠ Facebook: ⁠https://e-h-a.link/facebook⁠ LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠
January 23 · 16 min
The Role of Artificial Intelligence in Hematology (featuring Dr Gregor Hormann)
[This is a Rerelease. Episode first published on November 22, 2024.]Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here. Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new classification algorithms, and innovative large language models (LLMs) assisting physicians in the diagnosis prediction. The take-home message? "AI will not replace physicians. However, physicians who use AI will replace those who don't." Host: Dr Wilson Lim Guest: Dr Gregor Hormann Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠Provide Feedback⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠https://ehaedu.org/Campus⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠ Facebook: ⁠https://e-h-a.link/facebook⁠ LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠
January 16 · 12 min
How Does Climate Change Affect Hematology Practice? (with Dr Stephen Hibbs)
[This is a Rerelease. Episode first published on November 1, 2024.] Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future. The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vectors. Dr. Hibbs describes also the surprising link between extreme heat during pregnancy and an increased risk of children developing ALL (acute lymphoblastic leukemia). He further discusses practice-changing initiatives, like using sevoflurane instead of desflurane as an anesthetic to reduce environmental impact, and explains his work on improving the logistics of blood transfusions to lessen their ecological footprint. Finally, Dr. Hibbs encourages hematologists to focus on actionable steps to minimize their environmental impact, advocating for practical changes in clinical practices and increased awareness of the healthcare sector's contribution to global emissions. Host: Dr Sarah de Vlieger Guest: Dr Stephen Hibbs Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠Provide Feedback⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠https://ehaedu.org/Campus⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠ Facebook: ⁠https://e-h-a.link/facebook⁠ LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠
January 13 · 16 min
Accelerating Clinical Trials with AI (with Dr Jan Moritz Middeke)
[This is a Rerelease. Episode first published on April 11, 2025.] Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design. Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies. If you want to know more: ⁠https://www.nature.com/articles/s41746-024-01076-x⁠ Host: Isabel Olivera-Martinez, PhD, Medical Writer  Guest: Dr. Jan Moritz Middeke Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠https://ehaedu.org/Campus⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠ Facebook: ⁠https://e-h-a.link/facebook⁠ LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠
Dec 12, 2025 · 18 min
EHA Junior Research Grant: Dr Ana Río-Machín’s Journey in AML Research and Collaborative Science
Join us for this interview with Dr Río-Machín from Autonomous University of Madrid in Spain as she discusses her research on rare subtypes of acute myeloid leukemia (AML), which she conducted thanks to the EHA Junior Research Grant. Her discovery of transcriptional activator of key leukemia drivers in one of these subtypes may pave way to new therapeutic approaches. Tune in to hear dr. Río-Machín‘s call for more collaborative research to achieve impactful results for patients in the future. Host: Isabel Olivera-Martinez, PhD, Medical Writer  Guest: Dr Ana Río-Machín Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Dec 8, 2025 · 26 min
Hematologists’ Role in the Management of Gaucher Disease (Prof Argiris Symeonidis and Prof Sam Salek)
Join us for this discussion between Prof Argiris Symeonidis from University of Patras in Greece and Prof Sam Salek from University of Hertfordshire in UK who focus on the role of the hematologist in the diagnosis and management of patients with Gaucher disease. Prof Symeonidis and Prof Salek are both experts in recognizing and treating this rare lysosomal storage disorder and share their recommendations for hematologists to ensure earlier detection of this disease. Host: Prof. Sam Salek, University of Hertfordshire, UK Guest: Prof. Argiris Symeonidis, University of Patras, Rion, Greece Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Nov 28, 2025 · 19 min
Navigating the Toughest Challenges in Hematology Nursing: Insights from HNHCP Leaders
Join us for this inspiring interview with Erik Aerts from University Hospital Zurich in Switzerland and Mairéad Ní Chonghaile from St. James’s Hospital in Ireland who discuss their extensive work within the Hematology Nurses & Healthcare Professionals Group (HNHCP). Erik, the President, and Mairéad, the Vice-President of HNHCP, describe their unwavering commitment to providing hematology education to nurses and other healthcare professionals to ensure the best possible care for their patients. Tune in to hear what their thoughts are on the future of nursing in hematology and how they envisage addressing its biggest challenges. Host: Isabel Olivera-Martinez, PhD, Medical Writer  Guests: Erik Aerts, Nurse Manager, University Hospital Zurich, Switzerland and President of Hematology Nurses & Healthcare Professionals Group (HNHCP) Mairéad Ní Chonghaile, Bone Marrow Transplant Coordinator, St. James’s Hospital, Dublin, Ireland and Vice-President of HNHCP Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/ Facebook: https://e-h-a.link/facebook LinkedIn: https://www.linkedin.com/company/eha/ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe